Note 10 – Subsequent Events

Subsequent to September 30, 2025, The Farkas Group, Inc. and Michael D. Farkas, the Company’s President and Chairman, sold portions of their debt holdings to unrelated third parties. Each sold all accrued interest and part of the principal. Following the sales, The Farkas Group retained $352,019 and Mr. Farkas retained $361,543 of principal, which were later converted into shares of the Company’s common stock at $0.25 per share, as described in Item 5 – Other Information.

In addition, 16th Ave. Associates sold its debt holdings to two unrelated third parties. The Company was not a party to these sales and received no proceeds. That debt was also then converted into common stock at $0.25 per share.

On October 18, 2025, the President of Balance Labs Inc. loaned the company $18,000 under a promissory note bearing interest at 18% per annum, accruing from September 18, 2025, with a maturity date of October 18, 2026. The loan is unsecured and constitutes a related-party transaction.

On November 3, 2025, the company entered into a promissory note with The Farkas Group, Inc. for $250,000 at an interest rate of 8% per annum, accruing from November 3, 2025, and maturing on November 3, 2026. The note is a related-party transaction

On November 7, 2025, the Company’s Board of Directors approved the conversion of outstanding promissory notes totaling $4,166,946.69 (the “Debt”) owed to Michael Farkas and entities owned by Michael Farkas, its President and Chairman of the Board of Directors, and other third-party lenders (collectively, the “Lenders”). Pursuant to conversion notices received from the Lenders, the Debt was converted into 16,667,788 shares of restricted common stock at a conversion price of $0.25 per share.

On November 7, 2025, the Board of Directors of Balance Labs Inc. approved the issuance of an aggregate 8,563,008 shares of common stock at a price of $0.25 per share to certain employees, executives, and consultants of the company. The shares were issued as fully paid and non-assessable and represent equity compensation pursuant to individual agreements approved by the Board.

On November 11, 2025, the company entered into a promissory note with The Farkas Group, Inc. for $250,000 at an interest rate of 8% per annum, accruing from November 11, 2025, and maturing on November 11, 2026. The note is a related-party transaction